<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259086</url>
  </required_header>
  <id_info>
    <org_study_id>1920201</org_study_id>
    <nct_id>NCT04259086</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and
      safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of
      Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving a score of 0 (none) or 1 (mild) in Glabellar Line severity at maximum contraction at Week 4 as assessed by the Investigator Global Assessment Frown Wrinkle Severity (IGA-FWS)</measure>
    <time_frame>Screening - Week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects achieving a score of 0 (none) or 1 (mild) in Forehead Lines severity at maximum contraction at Week 4 as assessed by the Investigator Global Assessment Forehead Wrinkle Severity (IGA-FHWS)</measure>
    <time_frame>Screening - Week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects achieving a score of 0 (none) or 1 (mild) in Lateral Canthal Line severity at maximum contraction at Week 4 as assessed by the Investigator Global Assessment of Lateral Canthal Wrinkle Severity (IGA-LCWS)</measure>
    <time_frame>Screening - Week 36</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence, severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) during the overall study duration. [ Time Frame: Screening - Week 36 ]</measure>
    <time_frame>Screening - Week 36</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Upper Facial Lines (Glabellar Lines, Forehead Lines, &amp; Lateral Canthal Lines)</condition>
  <arm_group>
    <arm_group_label>DAXI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL) &amp; Lateral Canthal Lines (LCL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaxibotulinumtoxinA for injection</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>DAXI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent consistent with International Conference on
             Harmonisation-Good Clinical Practice (ICH-GCP) guidelines and local laws, including
             authorization to release health information, signed prior to any study procedures
             being performed

          2. Be outpatient, male or female subjects, in good general health, 18 years of age or
             older

          3. Have a score of moderate (2) or severe (3) Glabellar Lines during maximum contraction
             as assessed by the Investigator Global Assessment-Frown Wrinkle Severity (IGA-FWS) and
             Patient Frown Wrinkle Severity (PFWS)

          4. Have a score of moderate (2) or severe (3) Forehead Lines during maximum contraction
             as assessed by the Investigator Global Assessment Forehead Wrinkle Severity (IGA-FHWS)
             and Patient Forehead Wrinkle Severity (PFHWS)

          5. Have a score of moderate (2) or severe (3) Lateral Canthal Lines at maximum
             contraction as assessed by the Investigator Global Assessment of Lateral Canthal
             Wrinkle Severity (IGA-LCWS) and Patient Lateral Canthal Wrinkle Severity (PLCWS)
             (scores must be consistent bilaterally for each scale considered separately)

          6. Able to understand the requirements of the study and be willing and able to follow all
             study procedures, attend all scheduled visits, comprehend and complete the
             questionnaires without outside assistance and successfully complete the study

        Exclusion Criteria:

          1. Active skin disease, infections, or inflammation at the injection sites

          2. Planned or anticipated need for surgery or hospitalization through the end of the
             study

          3. Pregnant, nursing, or planning a pregnancy during the study; or is a Women of Child
             Bearing Potential (WOCBP) but is not willing to use an effective method of
             contraception

          4. Current enrollment in an investigational drug or device study or participation in such
             a study within the last 30 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dom Vitarella</last_name>
    <role>Study Director</role>
    <affiliation>Revance Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Manhattan Beach</city>
        <state>California</state>
        <zip>90266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5R3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lateral Canthal Wrinkle</keyword>
  <keyword>crow's feet lines</keyword>
  <keyword>LCL</keyword>
  <keyword>Forehead Lines</keyword>
  <keyword>Glabellar Lines</keyword>
  <keyword>Frown Lines</keyword>
  <keyword>Upper facial lines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

